As the incidence of Kovid increases, India seeks to increase vaccines through Russia’s Jab Deal


Prime Minister Narendra Modi’s government branded India as the “pharmacy of the world” before exporting more than 600 million doses of Oxford / AstraZeneca coronavirus jab locally.

But with irresistible hospitals for sick Kovid-19 patients in Mumbai, New Delhi and other major cities, the government is scrambling to secure more vaccines for household use.

On Monday, Indian drug regulators gave it urgent approval Russia’s Sputnik V vaccine, A day after the Kovid-9 was confirmed, the record came to 1,000,000. The agreement has widened the scope for both local production and potential imports of vaccines.

New Delhi also said that any foreign Covid-19 vaccine approved for use in the United States, the United Kingdom, Europe or Japan would be approved on an emergency basis to waive the earlier requirement of time-consuming local “bridge trials”.

Dr VK Paul, head of India’s Vaccine Strategy Task Force, said New Delhi hoped that drugmakers like Pfizer and Modarna would bring their vaccines to India “as soon as possible”.

However, experts warned that India’s latest measures are unlikely to significantly increase domestic vaccine supply. Due to its limited production capacity, job availability will remain tight for several months Serum Institute, The world’s largest vaccine maker, capable of producing 2.4 million doses of AstraZeneca a day, and Russia intends to export most jobs made in India.

Sputnik V’s sovereign asset fund for overseas sales and production, the Russian Direct Investment Fund, has contracts with at least five Indian pharmaceutical companies to produce a combined 850 million doses per year.

However, RDIF has announced an agreement to supply 100 million doses for domestic use only. The rest have been earmarked for export to more than 58 countries Place order For Russian Jab

“There is no immediate prospect of relief,” said Ruben Abraham, chief executive of the Mumbai-based think tank IDFC Institute. “It will take time for these vaccines to come online.”

To increase the anger of the people about the shortage of domestic vaccines. One of the most serious challenges in government Deadly second wave Covid-19 case.

Gajanan Dhuppu, 53, and his 47-year-old diabetic wife have confirmed the two-day separation at the JP Hospital in Nayadar, near New Delhi.

However, vaccines were spread before each occasion and hospital officials were unsure when more stocks would arrive. “The government is lying that there is no shortage,” Hypertension said in a smirk. “I wasted two days off from work trying to get vaccinated.”

Thousands attend Kumbh Mela, raising fears that Hindu festival Kovid-19 could turn into a highway event © Getty Images AFP

Many more vaccination centers in major cities across the country have been forced to suspend operations in recent days due to lack of jobs.

India Conducted The dose of about 108 m vaccine, or the national vaccine drive, began in mid-January, when caseloads were steadily declining, hence the dose of less than 8 per 100 people.

Although the older Indians were initially eligible for the job, they were reluctant to take them, he claimed Increased As case counts have increased in recent weeks. Authorities also extended eligibility for people over the age of 45 on April 1.

“Many people in the ICU at the moment were eligible for this vaccine and they never received it,” Abraham said.

Despite the limited quality, new vaccines in India may be the first of the Sputnik V in late this month or early May. However, financial services firm MK Global said in a note that production in India is unlikely to start before July.

Meanwhile, Dr. Reddy’s Laboratories, an Indian pharmaceutical manufacturer, aims to import Sputnik Dose to India after resolving price issues. The RDIF said it had a fixed price of $ 9.75 per dose for the double-dose vaccine, much higher than the dose India gives to the Serum Institute for AstraZeneca Jab. RDIF does not respond to requests for comment on pricing or quantities Will be exported.

RDIF chief Kirill Dimitriev said on Tuesday that the fund would soon announce “a few more” production contracts in India and that production of Sputnik V in the country would reach 50 million doses per month “by the end of the summer”.

However, companies partnering with RDIF have limited vaccine experience and will need time to set up production lines to make Sputnik V, analysts said. “There are a lot of tech transfers, then you have to get a manufacturing license. . . This is not an easy thing to do, it involves a lot of processes, ”said a company official.

New Delhi’s sudden push for vaccine collection came as many feared the growing case pressure was imminent after a political rally and Religious festivals.

Dr Swarup Sarkar, a member of the Covid-19 task force of the Indian Council of Medical Research, said the country was facing the consequences. Not accepted An aggressive vaccination strategy.

Instead, New Delhi planned to vaccinate only 300 million people with a vaccine considered a risk to death.

“India has made a strategic mistake,” the government said. “Achieving 70 percent immunity before mutations were not part of the government’s plan.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *